Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models
These results furnish comprehensive preclinical evidence for STSA-1002 as an innovative anti-C5a therapeutic agent and provide a preliminary rationale for developing immunomodulatory therapy in ARDS.
Authors
- Xinghe Wang (ORCID: https://orcid.org/0000-0002-4197-8545)
- Xin Zang
- Chang Xu
- Jingyi Zhang (ORCID: https://orcid.org/0000-0003-2316-6436)
- Xiaoqian Wang (ORCID: https://orcid.org/0000-0002-8675-9311)
- Ju Liu (ORCID: https://orcid.org/0000-0001-9932-2613)
- Qing Zhu (ORCID: https://orcid.org/0000-0003-2182-5709)
- Yingying Fang (ORCID: https://orcid.org/0000-0002-6187-2908)
Institutions
- Beijing Biocytogen (China) (CN)
- Beijing Shijitan Hospital (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.intimp.2025.115338
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00